ADENOCARD
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADENOCARD is an injectable small-molecule drug approved in 1989 by Astellas. The specific indication and mechanism of action are not documented in available data, limiting clinical context for career assessment.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30/100), suggesting declining team investment and potential role consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked jobs suggest limited current hiring momentum or diminished commercial priority. Roles are likely focused on margin defense and generic transition planning rather than growth.
Brand ManagerField Sales Representative
Worked on ADENOCARD at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.